Patients with Late-stage Nasopharyngeal Carcinoma Met Protein Expression Level Correlates with Survival in Updated

Met tyrosine kinase, the receptor for HGF/SF, is important in various cellular functions, including proliferation, mitogenesis, formation of branching tubules, angiogenesis, and tumor cell invasion and metastasis. However, the role of Met/HGF signaling pathway in nasopharyngeal carcinoma (NPC) has not been evaluated. In this study, we determined the expression profile and clinical correlation of Met/HGF in 66 cases of advanced NPC and the activation mechanisms of Met receptor in five NPC cell lines. Immunofluorescent staining and quantitative image analysis showed that the Met protein was expressed throughout the tumors and normal nasopharyngeal epithelia. Compared with NPC, the Met expression level was higher in columnar nasopharyngeal epithelium but lower in squamous nasopharyngeal epithelium. The normal interstitial stromal tissue expressed the lowest level of Met protein. HGF was detected mainly in the normal interstitial tissue surrounding the tumor. Met protein expression level was inversely correlated with patients’ survival time; the correlation coefficient was 0.319 (P 0.009). The mean survival time was 118 months in low Met expression group versus 52 months in high expression group (P 0.0004). The cumulative 5-year survival rate was 77.68% in low expression group versus 38.24% in high expression group. The clinical stage was also significantly more advanced in high Met expression group. In the multivariate analysis, both clinical stage and Met protein expression level were independent prognostic indicators for patient survival. All of the five NPC cell lines tested did not express hgf mRNA but expressed met mRNA, and tyrosine phosphorylation of Met protein was mainly induced by exogenous HGF stimulation in these cells. No mutation was found in the tyrosine kinase and the juxtamembrane domains of Met receptor in the five NPC cell lines tested. These results indicate that: (a) high Met protein expression level correlates with poorer survival in late-stage NPC and serves as an independent prognostic indicator; and (b) the Met receptor in NPC is activated by its paracrine ligand HGF from the interstitial tissues rather than by an autocrine loop or its activating mutation.

[1]  C. Van Waes,et al.  Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. , 2001, Cancer research.

[2]  T. Yoshizaki,et al.  Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. , 2001, The American journal of pathology.

[3]  G. V. Vande Woude,et al.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Rangell,et al.  Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. , 2001, The American journal of pathology.

[5]  E. Brown,et al.  Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. , 2001, Brain research. Molecular brain research.

[6]  S. Leung,et al.  Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.

[7]  I. Tsarfaty,et al.  Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. , 2000, Cytometry.

[8]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[9]  C. Qian,et al.  Combination of Angiogenesis Inhibitor TNP-470 with Cytotoxic Drugs in Experimental Therapy of Nasopharyngeal Carcinoma , 2000, The Annals of otology, rhinology, and laryngology.

[10]  S. Riordan,et al.  Hepatocyte growth factor/scatter factor‐induced intracellular signalling , 2000, International journal of experimental pathology.

[11]  Y. Zeng,et al.  Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma , 2000, Cancer.

[12]  J. Wee,et al.  Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma , 1999, Cancer.

[13]  I. Bièche,et al.  Alteration of Met protooncogene product expression and prognosis in breast carcinomas. , 1999, Analytical and quantitative cytology and histology.

[14]  S. Sato,et al.  Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. , 1999, Cancer.

[15]  A. Bardelli,et al.  Novel mutation in the ATP‐binding site of the MET oncogene tyrosine kinase in a HPRCC family , 1999, International journal of cancer.

[16]  D. Huntsman,et al.  Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. , 1999, The American journal of pathology.

[17]  G. Feng,et al.  Anti-Tumor Effect of Angiogenesis Inhibitor TNP-470 on the Human Nasopharyngeal Carcinoma Cell Line NPC/HK1 , 1999, Oncology.

[18]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[19]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[20]  L. Schmidt,et al.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. , 1999, Cancer research.

[21]  M. Fiscella,et al.  The mutationally activated Met receptor mediates motility and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Bardelli,et al.  Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. , 1998, The Biochemical journal.

[23]  Y. Ye,et al.  Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470) , 1998, The Journal of Laryngology & Otology.

[24]  P. Choyke,et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.

[25]  J. Cooper,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Qian,et al.  Primary study of neovasculature correlating with metastatic nasopharyngeal carcinoma using computer image analysis , 1997, Journal of Cancer Research and Clinical Oncology.

[27]  L. Schmidt,et al.  Activating mutations for the met tyrosine kinase receptor in human cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Weichselbaum,et al.  Nasopharyngeal carcinoma , 1997, The Lancet.

[29]  S. Scherer,et al.  Gene structure of the human MET proto-oncogene , 1997, Oncogene.

[30]  K. Matsumoto,et al.  Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. , 1997, Cancer research.

[31]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[32]  P. Humphrey,et al.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. , 1995, The American journal of pathology.

[33]  Zhang Feng,et al.  A new staging system for nasopharyngeal carcinoma in China. , 1994, International journal of radiation oncology, biology, physics.

[34]  H. Friess,et al.  Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. , 1994, Cancer research.

[35]  E. Castrén,et al.  Expression and functional interaction of hepatocyte growth factor- scatter factor and its receptor c-met in mammalian brain , 1994, The Journal of cell biology.

[36]  J. Armand,et al.  Nasopharyngeal cancer: epidemiology, staging, and treatment. , 1994, Seminars in oncology.

[37]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[38]  D. Huang,et al.  Nasopharyngeal carcinoma: Genetic changes, epstein–barr virus infection, or both: A clinical and molecular study of 36 patients , 1993, Cancer.

[39]  G. V. Vande Woude,et al.  Met expression and sarcoma tumorigenicity. , 1993, Cancer research.

[40]  C. Birchmeier,et al.  Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development , 1993, The Journal of cell biology.

[41]  F. Zhang,et al.  Infiltrating Lymphocytes and Accessory Cells in Nasopharyngeal Carcinoma1 , 1993, Japanese journal of cancer research : Gann.

[42]  T. Nakamura,et al.  Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[43]  T. Nakamura,et al.  Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. , 1993, Cancer research.

[44]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[45]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[46]  A. Seymour Histological Typing of Tumours of the Upper Respiratory Tract and Ear , 1991 .

[47]  S. Bianchi,et al.  Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance , 1991, The Laryngoscope.

[48]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[49]  J. Sham,et al.  Detection of subclinical riasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy , 1990, The Lancet.

[50]  C. Tsai,et al.  Establishment and characterization of two epithelial tumor cell lines (hne‐1 and hone‐1) latently infected with epstein‐barr virus and derived from nasopharyngeal carcinomas , 1990, International journal of cancer.

[51]  C. Cooper,et al.  Biosynthesis of the protein encoded by the c-met proto-oncogene. , 1989, Oncogene.

[52]  C. Cooper,et al.  Tyrosine kinase receptor indistinguishable from the c-met protein , 1989, Nature.

[53]  Michael Stoker,et al.  Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.

[54]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[55]  Z. Sizhong,et al.  Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma , 1983, International journal of cancer.

[56]  Y. F. Poon,et al.  Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx , 1980, International journal of cancer.

[57]  G. de‐Thé,et al.  Histopathology of nasopharyngeal carcinoma. Correlations with epidemiology, survival rates and other biological characteristics , 1979, Cancer.

[58]  L. Michaels,et al.  Undifferentiated carcinoma of the nasopharynx: a light and electron microscopical study. , 1977, Clinical otolaryngology and allied sciences.

[59]  M. al-Sarraf,et al.  Nasopharyngeal cancer. , 1999, Hematology/oncology clinics of North America.

[60]  A. Bardelli,et al.  Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor , 1998 .

[61]  E. Rosen,et al.  Regulation of angiogenesis by scatter factor. , 1997, EXS.

[62]  D. Huang,et al.  Detection of Epstein-Barr Virus DNA in well and poorly differentiated nasopharyngeal carcinoma cell lines. , 1996, Virus genes.

[63]  Y. F. Poon,et al.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. , 1992, International journal of radiation oncology, biology, physics.

[64]  D. Choy,et al.  Nasopharyngeal carcinoma and lymphoinfiltration. , 1991, Oncology.

[65]  P. Robinson The interpretation of diagnostic tests. , 1987, Nuclear medicine communications.

[66]  J. Rowley,et al.  The human met oncogene is related to the tyrosine kinase oncogenes , 1985, Nature.